Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry syrups, lyophilized vials, prefilled syringes, emulsion injection, and topicals. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.

Revenue projections:

Revenue projections for CAPLIPOINT
Revenue projections for CAPLIPOINT

CAPLIPOINT's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.

Financial Ratios:

currentRatio 6.70000
forwardPE 18.58906
debtToEquity 0.12700
earningsGrowth 0.19400
revenueGrowth 0.19000
grossMargins 0.60420
operatingMargins 0.30898
trailingEps 84.15000
forwardEps 106.95000

CAPLIPOINT's current ratio, being 6.7, demonstrates that the company has the liquidity necessary to service its short-term debt. With strong cash reserves and current assets, CAPLIPOINT is well-equipped to meet its immediate financial obligations without any difficulties.
CAPLIPOINT's Forward PE is in a reasonable range, indicating the stock is priced well relative to its earnings. The stock isn't overpriced, which leaves room for future growth, making it an attractive option for investors seeking value and long-term gains.
Caplin Point Laboratories Limited's positive earnings and revenue growth signal that the company is expected to expand its business. The company's increasing profits and sales reflect strong financial health, suggesting continued growth and success in the coming periods.
Positive gross and operating margins for CAPLIPOINT demonstrate the company's profitability. These margins reflect strong financial performance, with efficient operations contributing to the company's ability to generate consistent profits.
Caplin Point Laboratories Limited's forward EPS is higher than its trailing EPS, which signals that the company is expected to achieve greater profitability this financial year. This suggests improved earnings performance, indicating a positive outlook for Caplin Point Laboratories Limited's financial growth.

Price projections:

Price projections for CAPLIPOINT
Price projections for CAPLIPOINT

CAPLIPOINT's current valuation relative to projections shows a lack of distinct risks or opportunities. This neutral stance may lead investors to take a more conservative approach, maintaining their current positions until new information becomes available.

Recommendation changes over time:

Recommendations trend for CAPLIPOINT
Recommendations trend for CAPLIPOINT


Analysts' buy bias for CAPLIPOINT signals that the stock is considered a favorable investment. This outlook might prompt investors to allocate funds to CAPLIPOINT, seeing it as a solid and profitable choice to park their money and potentially benefit from the company's long-term growth.